PhaseBio Pharmaceuticals, a clinical-stage biotech focused on the development and commercialization of novel therapies for cardiopulmonary diseases, and BioVectra, a global contract development and manufacturing organization (CDMO), have entered a commercial scale supply agreement for the production of bentracimab, PhaseBio’s lead product candidate currently in a global Phase 3 clinical trial. Bentracimab is a novel, human monoclonal antibody fragment that in earlier clinical trials has shown im...